Trial Profile
a Phase II Trial With Continuous Intravenous Infusion of Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Jun 2019 Safety and efficacy results (n=50) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 30 Mar 2017 New trial record